Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged \>=18 to \<= 80 years, or minimum age of adult consent according to local regulations, at the Baseline Visit. Where locally permissible, participants 16 to \< 18 years of age who meet the definition of Tanner stage 5 for development at the Baseline Visit.~* Confirmed diagnosis of CD for at least 3 months prior to Baseline.~* Crohn's disease activity index (CDAI) score 220 - 450 at Baseline.~* Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF), abdominal pain (AP) score, and Simple Endoscopic Score for Crohn's Disease (SES-CD).~* Demonstrated intolerance or inadequate response to biologic therapy for CD.~* If female, participant must meet the contraception recommendations.~Exclusion Criteria:~* Participant with a current diagnosis of ulcerative colitis or indeterminate colitis.~* Participants with unstable doses of concomitant Crohn's disease therapy.~* Receipt of Crohn's disease approved biologic agents (infliximab, adalimumab, certolizumab, vedolizumab, natalizumab within 8 weeks prior to Baseline or ustekinumab within 12 weeks prior to Baseline), or any investigational biologic or other agent or procedure within minimally 35 days or 5 half-lives prior to Baseline, whichever is longer.~* Prior exposure to p19 inhibitors (e.g., risankizumab).~* Complications of Crohn's disease.~* Having an ostomy or ileoanal pouch.~* Known active Coronavirus Disease 2019 (COVID-19) infection.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Risankizumab Dose 1 (Induction Period 1) (Type: EXPERIMENTAL): Participants randomized to receive risankizumab dose 1 in Induction Period 1.
- Risankizumab Dose 2 (Induction Period 1) (Type: EXPERIMENTAL): Participants randomized to receive risankizumab dose 2 in Induction Period 1.
- Placebo (Induction Period 1) (Type: PLACEBO_COMPARATOR): Participants randomized to receive placebo for risankizumab in Induction Period 1.
- Risankizumab Dose 1 (Induction Period 2) (Type: EXPERIMENTAL): Participants who received placebo in Period 1 and participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 1 administered by intravenous (IV) infusion in Period 2.
- Risankizumab Dose 2 (Induction Period 2) (Type: EXPERIMENTAL): Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 2 administered by subcutaneous (SC) injection in Period 2.
- Risankizumab Dose 3 (Induction period 2) (Type: EXPERIMENTAL): Participants with inadequate response at Week 12 in Period 1 randomized to receive risankizumab dose 3 administered by subcutaneous (SC) injection in Period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete